Document is current
Any future updates will be listed below
-
Authors
Faridar, Alireza
Gamez, Nazaret
Li, Daling
Wang, Yanling
Boradia, Reena
Thome, Aaron D.
Zhao, Weihua
Beers, David R.
Thonhoff, Jason R.
Nakawah, Mohammad O.
Román, Gustavo C.
Volpi, John J.
Toledo, Jon B.
George, Michael
Davis, Charles S.
Pascual, Belen
Grundman, Michael
Masdeu, Joseph C.
Appel, Stanley H.
-
Funding
Funding for this research was provided by:
Alzheimer’s Association (PTCG-21-1818034)
National Institutes of Health (R01AG077685, R01AG077685)
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 17 June 2025
First Online: 4 July 2025
Declarations
:
: The trial was approved by the Houston Methodist Research Institute (HMRI) institutional review board (IRB) committee. All patients signed informed consent prior to study enrolment.
: Not applicable.
: AF, ADT, JCM, JRT declares a conflict of interest as a consultant with Coya Therapeutics, Inc. SHA declares a conflict of interest as a consultant with Implicit Bioscience and scientific advisory board chair of Coya Therapeutics, Inc. DRB declares a conflict of interest as a consultant with Implicit Bioscience and Coya Therapeutics, Inc. MG is an employee of Global R&D Partners, LLC, which received consulting fees from HMRI. CD is an employee of CSD Biostatistics, Inc, which received consulting fees from HMRI. Remaining authors have no conflict of interest.
